Fortune February 5, 2024
A recently published study in the JAMA Health Forum of a cross-section of patients enrolled in Medicare in 2022, found that those at the highest risk for severe COVID-19 infection received COVID-19 therapy less often than those with the least risk.
“We went into the study to find out why adoption of an effective COVID-19 treatment for high-risk individuals in the U.S. was so low,” says senior study author Michael L. Barnett, M.D., Associate Professor, Health Policy and Management, Harvard T. H. Chan School of Public Health. “Our first task was to identify the people who were using it.”
“When we looked at different COVID-19 risk factors, the people at highest risk should be getting treated anywhere from five to...
Today's Sponsors
Today's Sponsor